-
Something wrong with this record ?
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
LM. Ørnbjerg, CH. Brahe, L. Linde, L. Jacobsson, MJ. Nissen, EK. Kristianslund, MJ. Santos, D. Nordström, Z. Rotar, B. Gudbjornsson, F. Onen, C. Codreanu, U. Lindström, B. Möller, TK. Kvien, A. Barcelos, KK. Eklund, M. Tomšič, TJ. Love, G. Can,...
Language English Country France
Document type Journal Article, Multicenter Study
- MeSH
- Antirheumatic Agents therapeutic use MeSH
- Adult MeSH
- Remission Induction * methods MeSH
- Tumor Necrosis Factor Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Prospective Studies MeSH
- Arthritis, Psoriatic * drug therapy MeSH
- Registries * MeSH
- Aged MeSH
- Severity of Illness Index * MeSH
- Tumor Necrosis Factor-alpha antagonists & inhibitors MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Europe MeSH
OBJECTIVE: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. METHODS: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted Cox regression analyses and Chi-squared test, respectively). RESULTS: We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67-70%) and 66% (64-68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi). Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi. CONCLUSION: Two-thirds of patients remained on TNFi at 12months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.
Amsterdam Rheumatology and immunology Center Academic Medical Center Amsterdam The Netherlands
Center of Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Department of Rheumatology Geneva University Hospital Geneva Switzerland
GISEA registry Rheumatology Unit DETO University of Bari Bari Italy
Health Technology Assessment Agency Instituto de Salud Carlos 3 Madrid Spain
Inflammation Center Department of Rheumatology Helsinki University Hospital Helsinki Finland
Radboudumc Department of Rheumatology PO box 9101 6500 Nijmegen HB The Netherlands
Research Unit Sørlandet Hospital Kristianssand Norway
ROB FIN Registry Helsinki University and Helsinki University Hospital Helsinki Finland
TURKBIO Registry and Division of Rheumatology School of Medicine Dokuz Eylul University Izmir Turkey
University of Iceland Faculty of Medicine and Landspitali University Hospital Reykjavik Iceland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019933
- 003
- CZ-PrNML
- 005
- 20241024110857.0
- 007
- ta
- 008
- 241015s2024 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jbspin.2024.105729 $2 doi
- 035 __
- $a (PubMed)38582359
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. Electronic address: lykke.midtboell.oernbjerg@regionh.dk
- 245 10
- $a Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment / $c LM. Ørnbjerg, CH. Brahe, L. Linde, L. Jacobsson, MJ. Nissen, EK. Kristianslund, MJ. Santos, D. Nordström, Z. Rotar, B. Gudbjornsson, F. Onen, C. Codreanu, U. Lindström, B. Möller, TK. Kvien, A. Barcelos, KK. Eklund, M. Tomšič, TJ. Love, G. Can, R. Ionescu, AG. Loft, H. Mann, K. Pavelka, M. van de Sande, IE. van der Horst-Bruinsma, MP. Suarez, C. Sánchez-Piedra, GJ. Macfarlane, F. Iannone, B. Michelsen, LH. Hyldstrup, NS. Krogh, M. Østergaard, ML. Hetland
- 520 9_
- $a OBJECTIVE: To investigate real-world retention and remission rates in PsA patients initiating a 2nd or 3rd TNFi and the association with reason for discontinuation from the previous TNFi-treatment. METHODS: Prospectively collected routine care data from 12 European registries were pooled. Retention rates (Kaplan-Meier estimation) and crude/LUNDEX-adjusted rates of Disease Activity Score 28 and Disease Activity index for PSoriatic Arthritis (DAS28 and DAPSA28) remission were calculated and compared with adjusted Cox regression analyses and Chi-squared test, respectively). RESULTS: We included 5233 (2nd TNFi) and 1906 (3rd TNFi) patients. Twelve-month retention rates for the 2nd and 3rd TNFi were 68% (95%CI: 67-70%) and 66% (64-68%), respectively. Patients who stopped the previous TNFi due to AE/LOE had 12-month retention rates of 66%/65% (2nd TNFi), and 65%/63% (3rd TNFi), respectively. Patients who stopped the previous TNFi due to LOE after less vs more than 24 weeks had 12-month retention rates of 54%/69% (2nd TNFi), and 58%/65% (3rd TNFi). Six-month crude/LUNDEX-adjusted DAS28 remission rates were 48%/35% and 38%/27%, and DAPSA28 remission rates were 19%/14% and 14%/10%, for the 2nd and 3rd TNFi. CONCLUSION: Two-thirds of patients remained on TNFi at 12months for both the 2nd and 3rd TNFi, while one-third and one-quarter of patients were in DAS28 remission after 6months on the 2nd and 3rd TNFi. While drug effectiveness was similar in patients who stopped the previous TNFi due to AE compared to overall LOE, drug effectiveness was better in patients who had stopped the previous TNF due to secondary LOE compared to primary LOE.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a psoriatická artritida $x farmakoterapie $7 D015535
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a registrace $7 D012042
- 650 12
- $a indukce remise $x metody $7 D012074
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a TNF-alfa $x antagonisté a inhibitory $7 D014409
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Brahe, Cecilie Heegaard $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Linde, Louise $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Jacobsson, Lennart $u Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
- 700 1_
- $a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
- 700 1_
- $a Kristianslund, Eirik Klami $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Santos, Maria José $u Reuma.pt registry; Department of Rheumatology-Hospital Garcia de Orta, Almada and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- 700 1_
- $a Nordström, Dan $u ROB-FIN Registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Rotar, Ziga $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research (ICEBIO), University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a Onen, Fatos $u TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey
- 700 1_
- $a Codreanu, Catalin $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Lindström, Ulf $u Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
- 700 1_
- $a Möller, Burkhard $u Leitender Arzt der Universitätsklinik für Rheumatologie, Immunologie und Allergologie Inselspital, Bern, Switzerland
- 700 1_
- $a Kvien, Tore K $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Barcelos, Anabela $u Reuma.pt registry, Rheumatology Department - Centro Hospitalar do Baixo Vouga, Aveiro and Comprehensive Health Research Center (CHRC), NOVA University of Lisbon, Lisboa, Portugal
- 700 1_
- $a Eklund, Kari K $u Inflammation Center, Department of Rheumatology, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Tomšič, Matija $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Love, Thorvardur Jon $u University of Iceland, Faculty of Medicine, and Landspitali University Hospital, Reykjavik, Iceland
- 700 1_
- $a Can, Gercek $u TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey
- 700 1_
- $a Ionescu, Ruxandra $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Loft, Anne Gitte $u DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a van de Sande, Marleen $u Amsterdam UMC, University of Amsterdam, Department of Clinical Immunology and Rheumatology, Amsterdam, The Netherlands; Amsterdam Rheumatology & immunology Center (ARC), Academic Medical Center, Amsterdam, The Netherlands
- 700 1_
- $a van der Horst-Bruinsma, I E $u Radboudumc, Department of Rheumatology, PO box 9101, 6500 Nijmegen, HB, The Netherlands
- 700 1_
- $a Suarez, Manuel Pombo $u Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Santiago, Spain
- 700 1_
- $a Sánchez-Piedra, Carlos $u Health Technology Assessment Agency, Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group) University of Aberdeen, Aberdeen, United Kingdom
- 700 1_
- $a Iannone, Florenzo $u GISEA registry, Rheumatology Unit-DETO, University of Bari, Bari, Italy
- 700 1_
- $a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland; Research Unit, Sørlandet Hospital, Kristianssand, Norway
- 700 1_
- $a Hyldstrup, Lise Hejl $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Krogh, Niels Steen $u Zitelabs Aps, Copenhagen, Denmark
- 700 1_
- $a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 773 0_
- $w MED00005823 $t Joint bone spine $x 1778-7254 $g Roč. 91, č. 4 (2024), s. 105729
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38582359 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110851 $b ABA008
- 999 __
- $a ok $b bmc $g 2202262 $s 1231906
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 91 $c 4 $d 105729 $e 20240404 $i 1778-7254 $m Joint bone spine $n Joint Bone Spine $x MED00005823
- LZP __
- $a Pubmed-20241015
